CJC-1295

Overview

CJC-1295 is a synthetic analogue of growth hormone releasing hormone, the signal with which the hypothalamus prompts the pituitary to release GH. It is one of the most widely used peptides in this field and, at the same time, one of the most frequently misused — because two fundamentally different substances circulate under the same name.

The difference lies in a modification called DAC. It determines whether the peptide works for half an hour or for several days, and it changes the dosing by a factor of well over ten.

Mechanism of Action

GHRH binds to receptors in the pituitary and prompts the release of stored growth hormone. CJC-1295 mimics this signal, modified so that enzymes do not break it down within minutes as they do the natural hormone.

The variant without DAC — often sold as Mod GRF 1-29 — has a half-life of roughly thirty minutes. It produces a short, sharp GH pulse similar to the natural one and is injected several times a day in microgram amounts.

The variant with DAC carries an additional component that binds it to albumin in the blood. This extends the half-life to six to eight days, permitting a weekly injection in milligram amounts. The convenience is obvious, but it comes at a physiological cost: growth hormone is normally released in pulses, and the DAC variant flattens this rhythm into a continuous elevation. Side effects that scale with sustained GH exposure — water retention, insulin resistance — are more pronounced as a result.

Combination with a GHRP such as ipamorelin is the established practice because the two act on different receptors. GHRH increases the amount available for release; the GHRP triggers the release. Together they produce a stronger pulse than either alone.

Typical Context

The non-DAC variant is used two to three times a day, generally at one hundred micrograms and usually combined with ipamorelin in the same syringe. This is the physiologically closer approach and the more common one in practice.

The DAC variant is used where injection frequency is the deciding factor. One to two milligrams a week is enough, which is considerably more convenient — the trade-off is the loss of the pulsatile rhythm.

The confusion between the two is worth stating plainly, because the consequences are not trivial. A dose of one to two milligrams is correct for the DAC variant and a massive overdose for the non-DAC one. Products are frequently sold as "CJC-1295" without any indication of which they are. An unclear label is not a detail here; it is a reason to leave the vial alone.

Side Effects & Risks

• Water retention, tingling hands, joint discomfort
• Rising blood glucose and reduced insulin sensitivity, more pronounced with the DAC variant
• Fatigue after administration
• Headache, flushing shortly after injection
• Local reactions at the injection site
• Suppression of the natural GH rhythm, particularly with continuous DAC use
• Uncertain product quality and unclear DAC labelling on the grey market

Blood Work & Monitoring

• IGF-1 — the practical measure of GH activity
• Fasting glucose and HbA1c — the limiting factor for duration
• Thyroid values (TSH, fT3, fT4) — GH activity influences thyroid conversion

Harm-Reduction Notes

• Establish first whether the product contains DAC; the dosing differs by more than a factor of ten
• Without DAC: µg several times a day. With DAC: mg once or twice a week. Mixing these up is the central risk
• The non-DAC variant preserves the pulsatile rhythm and is physiologically the closer option
• Cycle 8–12 weeks with genuine breaks
• Water retention and tingling hands mean the dose is too high
• Check glucose for prolonged use
• Reconstitute with bacteriostatic water, store refrigerated, observe shelf life